Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AFDICAL Advance is a multi-ingredient bone health supplement developed and marketed by Anglo-French Drugs & Industries. It is formulated as a combination of calcium carbonate, vitamin D3 (cholecalciferol), and essential minerals including magnesium oxide and zinc sulfate. The product is designed to support bone mineral density, prevent osteoporosis, and address nutritional deficiencies in calcium and vitamin D. It functions by providing the structural components necessary for bone mineralization and enhancing the intestinal absorption of calcium through the activation of the vitamin D receptor. As a nutraceutical and over-the-counter (OTC) pharmaceutical product, it is primarily used for the maintenance of skeletal integrity and the prevention of bone-related disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AFDICAL Advance.